CEREVEL NOTIFICATION: Think $45 Per Share is Too Low for Cerevel (Nasdaq:CERE)? Contact BFA Law about Ongoing Investigation into the Acquisition PriceAccesswire • 06/17/24
CEREVEL INVESTOR ALERT: Think $45 Per Share is Too Low for Cerevel (Nasdaq:CERE)? BFA Law Reminds You to Contact the Firm about Ongoing Investigation into the Deal PriceAccesswire • 06/14/24
BFA Law Notice: Cerevel (Nasdaq:CERE) Shareholders are Encouraged to Contact the Firm about Investigation into Whether the $45 Per Share Offer is EnoughAccesswire • 06/13/24
Calling All Cerevel Therapeutics Holdings, Inc. (CERE) Investors: Contact Bronstein, Gewirtz & Grossman, LLC To Claim Your LossesAccesswire • 06/13/24
CEREVEL SHAREHOLDER REMINDER: Is $45 Per Share Enough for Cerevel (Nasdaq: CERE)? BFA Law is Investigating and Encourages Investors to Contact the FirmGlobeNewsWire • 06/13/24
CEREVEL MERGER NEWS: Is $45 Per Share Enough for Cerevel (Nasdaq: CERE)? BFA Law is Investigating and Reminds Investors to Contact the Firm About Your RightsAccesswire • 06/12/24
CEREVEL STOCK NEWS: BFA Law Investigates Cerevel (Nasdaq:CERE) Following $45 Per Share Acquisition Offer, Investors are Reminded to Contact the FirmAccesswire • 06/11/24
CEREVEL SHAREHOLDER ALERT: Kaskela Law LLC Announces Investigation into Fairness of Cerevel Therapeutics Holdings, Inc. (NASDAQ: CERE) Buyout and Encourages Investors to Contact the FirmBusiness Wire • 06/11/24
CEREVEL ALERT: Is $45 Per Share Too Low for Cerevel (Nasdaq: CERE)? BFA Law is Investigating and Urges Shareholders to Contact the Firm About Your RightsGlobeNewsWire • 06/11/24
After Plunging -5.14% in 4 Weeks, Here's Why the Trend Might Reverse for Cerevel Therapeutics (CERE)Zacks Investment Research • 06/10/24
CEREVEL INVESTIGATION NOTICE: Cerevel (CERE) Shareholders are Encouraged to Contact BFA Law About Their Rights in the $45 Merger Offer from AbbVieAccesswire • 06/10/24
CEREVEL NEWS NOTIFICATION: BFA Law Alerts Cerevel (Nasdaq: CERE) Shareholders of Investigation into the $45 Merger Offer, Contact the Firm About Your RightsGlobeNewsWire • 06/08/24
CEREVEL NEWS ALERT: BFA Law Announces Investigation of Cerevel (Nasdaq:CERE) Over the $45 Merger Offer, Investors are Encouraged to Contact the FirmAccesswire • 06/07/24
CEREVEL INVESTIGATION UPDATE: Cerevel (Nasdaq: CERE) Shareholders are Urged to Contact BFA Law about the $45 Merger Offer from AbbVieAccesswire • 06/06/24
CEREVEL INVESTIGATION ALERT: Cerevel (Nasdaq: CERE) Investors are Encouraged to Contact BFA Law about the $45 Merger Offer from AbbVieGlobeNewsWire • 06/05/24
CEREVEL SHAREHOLDER ALERT: Cerevel Investors are Encouraged to Contact BFA Law About Ongoing Investigation into Whether the $45 Merger Offer is Too LowAccesswire • 06/05/24
ACQUISITION NOTICE: Cerevel's (CERE) $45 Merger Offer is Being Investigated by BFA Law for Being Too Low, Shareholders are Encouraged Contact the FirmAccesswire • 06/04/24
ACQUISITION NEWS: Cerevel's (Nasdaq: CERE) $45 Merger Offer is Being Investigated for Being Too Low, Shareholders are Encouraged Contact BFA LawGlobeNewsWire • 06/03/24
INVESTIGATION NOTICE (CERE): The $45 Per Cerevel Share Merger Offer Is Being Investigated by BFA Law for Being Too Low - Contact Firm for InformationAccesswire • 06/03/24
CEREVEL REMINDER: Cerevel (CERE) Shareholders are Encouraged to Inquire About BFA Law's Investigation into the $45 Merger Offer Being Too LowAccesswire • 05/31/24
CERE SHAREHOLDERS: Cerevel Shareholders are Encouraged to Inquire About BFA Law's Investigation into the $45 Merger Offer Being Too LowAccesswire • 05/30/24
CEREVEL INVESTOR NOTICE: Kaskela Law LLC Announces Investigation of Cerevel Therapeutics Holdings, Inc. (NASDAQ: CERE) and Encourages Investors to Contact the FirmPRNewsWire • 05/30/24
NOTICE OF INVESTIGATION: Kaskela Law LLC Announces Shareholder Investigation of Cerevel Therapeutics Holdings, Inc. (NASDAQ: CERE) and Encourages Investors to Contact the FirmPRNewsWire • 05/20/24
